Compared to recent studies indicating that NLRP1 is activated and able to promote tumor growth in human melanoma by enhancing inflammasome activity [9,10,15], we infer that it is NLRP1, rather than NLRP3, that is down-regulated under CP treatment, thereby attenuating the melanoma inflammatory microenvironment. The gene discussed is NLRP3; the disease is neoplasm.